Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Cherylle Goebel"'
Autor:
Cherylle Goebel, Christopher L. Louden, Robert Mckenna, Osita Onugha, Andrew Wachtel, Thomas Long
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-11 (2020)
Abstract Background In a previous study (Goebel et. al, Cancer Genomics Proteomics 16:229-244, 2019), we identified 33 biomarkers for an early stage (I-II) Non-Small Cell Lung Cancer (NSCLC) test with 90% accuracy, 80.3% sensitivity, and 95.4% specif
Externí odkaz:
https://doaj.org/article/0441ecc0ad5a48ea83df7edef5e7aef3
Autor:
Thomas C. Long, Osita Onugha, Cherylle Goebel, Robert Mckenna, Andrew Wachtel, Christopher Louden
Publikováno v:
Cancer Genomics - Proteomics. 16:229-244
Background/aim In 2016 in the United States, 7 of 10 patients were estimated to die following lung cancer diagnosis. This is due to a lack of a reliable screening method that detects early-stage lung cancer. Our aim is to accurately detect early stag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b92ab567a97d3ff63486710f241e67b6
https://doi.org/10.21873/cgp.20128
https://doi.org/10.21873/cgp.20128
Autor:
Cherylle Goebel, Louden, Christopher, Mckenna, Robert, Osita Onugha, Wachtel, Andrew, Long, Thomas
Additional file 1. Supplementary Figure 1. Immunoassay Procedure.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b3125a3dcf5fc1c1365130bf1859276
Autor:
Cherylle Goebel, Louden, Christopher, Mckenna, Robert, Osita Onugha, Wachtel, Andrew, Long, Thomas
Additional file 2. Supplementary Table 1. Actual and predicted results using the LCDT1 Algorithm.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::018e905368d19a74551a453301d1b43f
Autor:
Cherylle Goebel, Andrew Wachtel, Robert Mckenna, Osita Onugha, Christopher Louden, Thomas C. Long
Publikováno v:
BMC Cancer
BMC Cancer, Vol 20, Iss 1, Pp 1-11 (2020)
BMC Cancer, Vol 20, Iss 1, Pp 1-11 (2020)
Background In a previous study (Goebel et. al, Cancer Genomics Proteomics 16:229-244, 2019), we identified 33 biomarkers for an early stage (I-II) Non-Small Cell Lung Cancer (NSCLC) test with 90% accuracy, 80.3% sensitivity, and 95.4% specificity. Fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35854f5613d4d6d170fd3e02afa05308
https://pubmed.ncbi.nlm.nih.gov/32085733
https://pubmed.ncbi.nlm.nih.gov/32085733